E. van Meerten

888 total citations
15 papers, 499 citations indexed

About

E. van Meerten is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. van Meerten has authored 15 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 9 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. van Meerten's work include Colorectal Cancer Surgical Treatments (7 papers), Colorectal and Anal Carcinomas (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). E. van Meerten is often cited by papers focused on Colorectal Cancer Surgical Treatments (7 papers), Colorectal and Anal Carcinomas (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). E. van Meerten collaborates with scholars based in Netherlands, Italy and Germany. E. van Meerten's co-authors include Ate van der Gaast, Cornelis Verhoef, Joost Rothbarth, Karin Müller, Herman van Dekken, JHM Schellens, Jaap Verweij, Jun Ma, A.S.T. Planting and M de Boer-Dennert and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Leukemia.

In The Last Decade

E. van Meerten

15 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. van Meerten Netherlands 11 280 276 238 67 64 15 499
Makio Gamoh Japan 11 328 1.2× 109 0.4× 248 1.0× 60 0.9× 73 1.1× 49 484
Stefania Di Girolamo Italy 11 147 0.5× 101 0.4× 145 0.6× 37 0.6× 55 0.9× 28 330
Vincent Hautefeuille France 13 364 1.3× 167 0.6× 146 0.6× 33 0.5× 60 0.9× 58 508
A. Fandi France 6 292 1.0× 108 0.4× 207 0.9× 49 0.7× 39 0.6× 7 473
Madhavan V. Pillai United States 7 419 1.5× 108 0.4× 133 0.6× 59 0.9× 49 0.8× 15 512
M Findlay United Kingdom 6 511 1.8× 361 1.3× 659 2.8× 106 1.6× 69 1.1× 8 890
Naofumi Eriguchi Japan 16 324 1.2× 385 1.4× 216 0.9× 69 1.0× 72 1.1× 60 716
N. Malavasi Italy 8 338 1.2× 306 1.1× 128 0.5× 25 0.4× 83 1.3× 17 424
Elisabetta Alafaci Italy 4 473 1.7× 185 0.7× 152 0.6× 40 0.6× 54 0.8× 7 580
Xiaoling Ou United States 8 276 1.0× 91 0.3× 409 1.7× 184 2.7× 53 0.8× 12 573

Countries citing papers authored by E. van Meerten

Since Specialization
Citations

This map shows the geographic impact of E. van Meerten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. van Meerten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. van Meerten more than expected).

Fields of papers citing papers by E. van Meerten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. van Meerten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. van Meerten. The network helps show where E. van Meerten may publish in the future.

Co-authorship network of co-authors of E. van Meerten

This figure shows the co-authorship network connecting the top 25 collaborators of E. van Meerten. A scholar is included among the top collaborators of E. van Meerten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. van Meerten. E. van Meerten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Nuyttens, Joost J., Esther Oomen‐de Hoop, Jeroen L.A. van Vugt, et al.. (2021). Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. BMC Gastroenterology. 21(1). 313–313. 3 indexed citations
2.
Hagemans, J.A.W., Joost Rothbarth, Guido H W van Bogerijen, et al.. (2019). Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma. Annals of Surgical Oncology. 26(4). 1134–1141. 8 indexed citations
3.
Hagemans, J.A.W., W Alberda, Joost Rothbarth, et al.. (2019). Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. European Journal of Surgical Oncology. 46(3). 448–454. 55 indexed citations
4.
Nierop, Pieter M. H., M. Verseveld, Boris Galjart, et al.. (2018). The liver-first approach for locally advanced rectal cancer and synchronous liver metastases. European Journal of Surgical Oncology. 45(4). 591–596. 14 indexed citations
5.
Hagemans, J.A.W., Joost Rothbarth, Wim J. Kirkels, et al.. (2018). Total pelvic exenteration for locally advanced and locally recurrent rectal cancer in the elderly. European Journal of Surgical Oncology. 44(10). 1548–1554. 18 indexed citations
6.
Kwakman, Johannes J.M., Geraldine R. Vink, Laurens V. Beerepoot, et al.. (2017). Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. International Journal of Clinical Oncology. 23(3). 482–489. 27 indexed citations
7.
Alberda, W, Brigitte C.M. Haberkorn, Joost J. Nuyttens, et al.. (2015). Response to chemotherapy in patients with recurrent rectal cancer in previously irradiated area. International Journal of Colorectal Disease. 30(8). 1075–1080. 8 indexed citations
8.
Ayez, Ninos, Eric P. van der Stok, Dirk J. Grünhagen, et al.. (2015). The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. European Journal of Surgical Oncology. 41(7). 859–867. 48 indexed citations
9.
Meerten, E. van, Margot Tesselaar, Karen J. Neelis, et al.. (2010). Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: A phase II study.. Journal of Clinical Oncology. 28(15_suppl). e14508–e14508. 17 indexed citations
10.
Meerten, E. van, Ate van der Gaast, H.W. Tilanus, et al.. (2009). Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The rotterdam experience. Journal of Surgical Oncology. 100(1). 32–37. 23 indexed citations
11.
Gool, Arthur R. Van, et al.. (2008). [Chemotherapy during clozapine treatment. Increased risk of agranulocytosis?].. PubMed. 50(10). 673–8. 2 indexed citations
12.
Meerten, E. van, et al.. (2007). First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. British Journal of Cancer. 96(9). 1348–1352. 37 indexed citations
13.
Meerten, E. van, Karin Müller, Hugo W. Tilanus, et al.. (2006). Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. British Journal of Cancer. 94(10). 1389–1394. 102 indexed citations
14.
Hagemeijer, A, et al.. (1998). Development of an interphase fluorescent in situ hybridization (FISH) test to detect t(8;21) in AML patients. Leukemia. 12(1). 96–101. 15 indexed citations
15.
Schellens, JHM, Jun Ma, A.S.T. Planting, et al.. (1996). Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. British Journal of Cancer. 73(12). 1569–1575. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026